Correlation between Tamoxifen-Metabolizing Enzymes Genotypes/Phenotypes and Clinical Outcomes in Patients with Breast Cancer Treated with Tamoxifen


Correlation between Tamoxifen-Metabolizing Enzymes Genotypes/Phenotypes and Clinical Outcomes in Patients with Breast Cancer Treated with Tamoxifen
Slides from presentations at SABCS 2010 and comments from an interview with Clifford Hudis, MD (1/12/11)
Leyland-Jones B et al. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. San Antonio Breast Cancer Symposium 2010;Abstract S1-8.

Rae JM et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. San Antonio Breast Cancer Symposium 2010;Abstract S1-7.

Dr Hudis is Chief of the Solid Tumor Division’s Breast Cancer Medicine Service in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and is Professor of Medicine at Weill Cornell Medical College in New York, New York.